Navigation Links
CNIO and Merck sign license agreement for the development of new cancer drugs
Date:12/18/2013

The Spanish National Cancer Research Centre (CNIO) and the German chemical and pharmaceutical company Merck today signed an agreement in Madrid to collaborate in the area of cancer drug development. This global option and license agreement will encourage the development and commercialisation of new compounds in the field of oncology.

With this agreement, the CNIO has granted to Merck exclusive rights to develop and commercialise their new inhibitors of the ataxia telangiectasia and Rad3-related (ATR) kinase. In exchange, Merck will make an initial payment along with other potential income of up to nearly 19 million euros, as well as royalties on net sales.

This agreement is the result of Merck Serono, the biopharmaceutical division of Merck, evaluating a group of ATR inhibitors developed entirely by the CNIO, via its Experimental Therapies Programme and the Genomic Instability Group, led by Joaqun Pastor and scar Fernndez-Capetillo, respectively.

Carmen Vela, Spanish Secretary of State for R&D, who signed the agreement as President of the CNIO Board of Trustees, expressed her satisfaction "at this public-private partnership between a world class research centre and one of the biggest pharmaceutical companies in the world." The Secretary of State underlined the need for "increasing involvement of the private sector in all aspects of Spanish R&D including execution and funding."

"Part of Merck's commitment to oncology includes the focus on strategic agreements that allow us to foster a constant flow of innovations," said Andree Blaukat, Head of Translational Innovation Platform Oncology for Merck Serono. "We are convinced that working with like-minded organizations, like the CNIO, will further strengthen our efforts towards finding the next generation of breakthrough therapies."

"As a research organisation, the CNIO is committed to fostering and promoting innovation. Among other initiatives, the CNIO's Experimental Therapeutics Program carries out early drug discovery projects. The CNIO is delighted to be working with Merck to hopefully translate this research into potential new treatment options for patients with cancer," said Mara Blasco, Director of the CNIO. "It is through collaborations with industry oncology leaders that we can bring CNIO discoveries, such as those made by the group led by Oscar Fernndez-Capetillo, to patients, and contribute new improved products to the battle against cancer."

The agreement encompasses the licensing of two series of ATR inhibitors, as well as a screening platform to validate the compounds, which have currently reached an advanced preclinical stage.

ATR kinase has an important role in the response to DNA damage and in facilitating cell survival. Due to the fact that tumour cells accumulate more DNA damage than healthy cells, blocking ATR kinase activity with selective inhibitors appears to be a strategy worth investigating further for specific tumour types.


'/>"/>

Contact: Nuria Noriega
comunicacion@cnio.es
Centro Nacional de Investigaciones Oncologicas (CNIO)
Source:Eurekalert

Related medicine news :

1. Fosamax Lawsuits Update: Rottenstein Law Group LLP Comments on Reported $28 Million Merck ‘Jaw Death’ Settlement
2. Merck for Mothers Supports UNICEF’s Efforts to Help Save Lives in South Africa
3. Fosamax Lawsuits Update: Rottenstein Law Group Responds to Femur Fracture Verdict in Merck’s Favor
4. Merck scientist Daria Hazuda presents Bernard Fields Lecture at 20th Conference on Retroviruses and Opportunistic Infections (CROI)
5. Merck and Regenstrief Institute establish evidence-based care collaboration
6. Miami Plastic Surgeon Jon Harrell Advises Patients to Always Use a Licensed Surgeon
7. For The First Time Ever Colorado Issues Recreational Marijuana Sales License
8. Fem Med Formulas Announces an Exclusive License Agreement with NewBridge Pharmaceuticals
9. Wayne State part of team for license on new ways to manage cancer with green tea extracts
10. SeniorQuote Insurance Services Licensed to Support Kansas
11. 265 NY Ambulance and ALS First Responders to Face Stricter License Requirements Regarding Narcotics – MedixSafe Provides Necessary & Reliable Narcotics Security Solutions
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... , ... June 27, 2016 ... ... the patient payment industry today announced its strategic partnership with Connance, a ... workflows. , The two companies’ proven, proprietary technology combine to provide health ...
(Date:6/26/2016)... (PRWEB) , ... June 26, 2016 , ... On June ... sponsor of the 2016 Cereal Festival and World’s Longest Breakfast Table in Battle Creek, ... of the city’s history as home to some of the world’s leading providers of ...
(Date:6/26/2016)... ... June 26, 2016 , ... Many women ... diagnosed with endometriosis. These women need a treatment plan to not only alleviate ... that can help for preservation of fertility and ultimately achieving a pregnancy. The ...
(Date:6/25/2016)... California (PRWEB) , ... June 25, 2016 , ... "With ... fit their specific project," said Christina Austin - CEO of Pixel Film Studios. ... customizable and all within Final Cut Pro X . Simply select a ProHand ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... On Friday, ... presented a Bronze Wellness at Work award to iHire in recognition of their exemplary ... part of the 7th annual Maryland Workplace Health & Wellness Symposium at the BWI ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... 2016 Dublin ... addition of the " Global Markets for Spectroscopy ... This report focuses on the ... review, including its applications in various applications. The report ... includes three main industries: pharmaceutical and biotechnology, food and ...
(Date:6/24/2016)... 2016 The Academy of Managed Care Pharmacy ... that would allow biopharmaceutical companies to more easily share ... formulary and coverage decisions, a move that addresses the ... The recommendations address restrictions in the sharing ... drug label, a prohibition that hinders decision makers from ...
(Date:6/24/2016)... SAN CLEMENTE, Calif. , June 24, 2016  American ... function testing company, is now able to perform sophisticated lung assessments ... ndd Medical Technologies , Inc. Patients are no ...  Thanks to ndd,s EasyOne PRO ® , ARL patients like Jeanne ... needed testing done in the comfort of her own home. ...
Breaking Medicine Technology: